In the Media

November 1, 2018

UBC’s Dr. Yadav Talks about How Biosynthesis May Efficiently Produce Cannabinoids

InMed and the laboratory of Dr. Vikramaditya Yadav at the University of British Columbia collaborate on a proprietary biosynthesis technology to produce bioidentical, high purity, high grade cannabinoids. The host selected is E.coli. In this video, Dr. Yadav talks how an E.coli-based system is uniquely suited for producing cannabinoids.

Source: BTV

Share this post

Latest Articles

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,

December 11, 2024

Study on Anti-Inflammation by Modulation of Endocannabinoid System

A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.

December 10, 2024

Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment

In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s

September 4, 2024